Progenics Pharmaceuticals Earnings: Everything You Must Know Now
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) had a loss and met Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company.
Progenics Pharmaceuticals Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share decreased to $-0.24 in the quarter versus EPS of $-0.32 in the year-earlier quarter.
Revenue: Decreased 1.1% to $1.8 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Progenics Pharmaceuticals Inc. reported adjusted EPS loss of $0.24 per share. By that measure, the company missed the mean analyst estimate of $-0.24. It missed the average revenue estimate of $1.86 million.
Key Stats (on next page)…
Revenue decreased 19.28% from $2.23 million in the previous quarter. EPS increased to $-0.24 in the quarter versus EPS of $-0.22 in the previous quarter.
Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.23 to a loss $0.24. For the current year, the average estimate has moved up from a loss of $0.91 to a loss of $0.75 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)